Chai Discovery secures $400 million as the AI-driven drug discovery sector experiences significant growth.

      Chai Discovery’s recent $400 million fundraising has increased its valuation to $3.8 billion in just seven months, nearly tripling its previous worth of $1.3 billion. This development signals a significant shift from potential to actual implementation in AI drug discovery.

      The San Francisco startup announced its successful Series C funding round, which was led by Index Ventures, with participation from Kleiner Perkins, Sequoia Capital, Dimension, and new investors such as Bain Capital Ventures, Battery Ventures, and Baillie Gifford. Returning supporters OpenAI and Thrive Capital also contributed additional funds.

      With this latest funding, Chai’s total raised capital surpasses $600 million within approximately eleven months. The company previously secured a $70 million Series A in mid-2025, followed by a $130 million round at a $1.3 billion valuation in December.

      Chai was established in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud, whose experiences include roles at OpenAI, Meta’s FAIR lab, and Stripe. The company aims to create new medications rather than merely discovering existing ones.

      While most drug discovery processes involve screening extensive libraries of existing compounds, Chai utilizes generative AI to create new antibodies and proteins tailored to specific disease targets prior to lab testing. Its 2025 Chai-2 model was the first zero-shot system for fully de novo antibody design to achieve double-digit success rates in laboratory tests, representing a hundredfold improvement over traditional methods. The newer Chai-3 model enhances binding to more difficult targets.

      Chai's technology is in active use, with models employed by Eli Lilly, Pfizer, and Novartis, and the company recently announced a partnership with the immunology firm argenx. This substantial commercial involvement sets Chai apart in a landscape where major pharmaceutical companies are typically hesitant to adopt untested software.

      The AI drug discovery field is becoming increasingly crowded and well-funded. Isomorphic Labs, a spinoff from Google DeepMind dedicated to drug discovery, completed a $2.1 billion funding round in May and counts Novartis as a partner. Xaira Therapeutics launched with $1 billion, while Recursion has raised over $1 billion. Major AI entities are also getting involved; for instance, Anthropic acquired a small drug design startup for roughly $400 million, and ByteDance has entered the competition. Researchers like Stanford’s James Zou are also founding their own AI-biology companies.

      Analysts estimate the AI drug discovery market will be valued at approximately $2.35 billion by 2025, expanding to $13.7 billion by 2033. Chai’s valuation tripling in just seven months indicates that investors are moving more rapidly than industry projections.

      However, challenges lie ahead. Although a model can produce candidate molecules in a matter of minutes, these candidates will still require years of laboratory work, clinical trials, and regulatory approval before they can be made available to patients. Chai and its competitors believe that the future of medicine relies on design rather than discovery. The ability of this belief to withstand the initial round of clinical setbacks is what the $3.8 billion valuation is truly evaluating.